Olmesartan/Amlodipine Hct (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide)

Olmesartan/Amlodipine HCT is a fixed‑dose combination that addresses elevated blood pressure through three complementary mechanisms.

• Essential hypertension: lowers systolic and diastolic pressure when monotherapy is insufficient.
• Uncontrolled hypertension: provides additional control in patients whose blood pressure remains above target despite other agents.
• Hypertension requiring diuretic therapy: adds volume reduction and sodium‑water excretion to improve overall control.

• Olmesartan blocks AT1 receptors, preventing angiotensin II‑mediated vasoconstriction; amlodipine inhibits calcium influx into vascular smooth muscle, causing arterial dilation; hydrochlorothiazide reduces Na⁺/Cl⁻ reabsorption in the distal convoluted tubule, promoting diuresis and decreasing plasma volume. The combined actions result in synergistic blood‑pressure reduction.

The following adverse reactions have been reported with the combination product.

Common Side Effects

• Dizziness: sensation of light‑headedness, especially after the first dose.
• Headache: mild to moderate intensity, often transient.
• Peripheral edema: swelling of ankles or feet due to vasodilation.
• Flushing: warm sensation and reddening of skin.
• Fatigue: general tiredness without exertion.
• Cough: occasional dry cough, more typical of ARB therapy.

Serious or Rare Side Effects

• Angioedema: rapid swelling of face, lips or throat, requiring emergency care.
• Severe hypotension: marked drop in blood pressure leading to fainting.
• Renal impairment: worsening kidney function, especially in patients with pre‑existing disease.
• Electrolyte disturbances: hyponatremia, hypokalemia or hyperkalemia.
• Hepatic dysfunction: abnormal liver enzymes or jaundice.

Before prescribing Olmesartan/Amlodipine HCT, clinicians should consider several safety aspects.

• Blood pressure monitoring: adjust therapy based on regular measurements.
• Renal function assessment: evaluate serum creatinine and eGFR, especially in the elderly.
• Electrolyte checks: monitor sodium and potassium levels due to the thiazide component.
• Pregnancy and lactation: avoid use unless benefits clearly outweigh risks.
• Concomitant potassium‑sparing agents: use with caution to prevent hyperkalemia.
• Store at ambient temperature: keep in the original pack, protect from moisture and direct sunlight.

Olmesartan/Amlodipine HCT may interact with several drug classes; some require avoidance while others need close monitoring.

Major Interactions (Avoid)

• ACE inhibitors: combined use increases risk of hyperkalemia and renal dysfunction.
• Potassium supplements or potassium‑sparing diuretics: may cause dangerous hyperkalemia.
• NSAIDs: can blunt antihypertensive effect and impair renal function.
• Cyclosporine: may raise serum concentrations of amlodipine.
• Lithium: increased lithium levels leading to toxicity.

Moderate Interactions (Monitor Closely)

• Other diuretics: additive diuretic effect may cause dehydration.
• Beta‑blockers: may enhance blood‑pressure lowering, requiring dose adjustments.
• Antidiabetic agents: risk of hypoglycemia due to improved glucose control.
• Strong CYP3A4 inhibitors: elevate amlodipine levels, monitor for edema.
• CYP2C9 inhibitors: may affect hydrochlorothiazide metabolism, watch electrolytes.